Erlotinib
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Erlotinib (ncit:C65530)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib | |
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib | |
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib | |
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib | |
| Sensitivity (+) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| Sensitivity (+) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Erlotinib | |
| Sensitivity (+) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Erlotinib |